Ventoux Biosciences

Ventoux Biosciences is a private, preclinical biotech firm developing novel therapies for immune-fibrotic diseases, with an initial focus on Dupuytren's disease and Spinal Cord Injury. Its lead program, VEN-201, emerged from an AI-driven discovery platform analyzing multi-omic data and represents a potential first disease-modifying pharmacologic therapy for Dupuytren's. The company is led by a team with deep expertise in biostatistics, fibrosis biology, and finance, and is currently advancing its pipeline through preclinical validation with a strong translational rationale. Ventoux operates as a pre-revenue entity, building a differentiated pipeline backed by robust intellectual property and patient insight.

AI-guided, multi-omic analysis platform for discovering novel immune-fibrotic targets.

In Dupuytren's, direct competition is minimal as no disease-modifying drugs are approved; competition is primarily from surgical and procedural interventions. In Spinal Cord Injury, the landscape is crowded with diverse therapeutic approaches (cell therapies, neuroprotection, rehabilitation), but few focus specifically on modulating the fibrotic component of secondary injury.